Banque Cantonale Vaudoise Increases Stake in Bristol Myers Squibb Company $BMY

Banque Cantonale Vaudoise boosted its stake in Bristol Myers Squibb Company (NYSE:BMY) by 10.3% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 113,102 shares of the biopharmaceutical company’s stock after purchasing an additional 10,555 shares during the quarter. Banque Cantonale Vaudoise’s holdings in Bristol Myers Squibb were worth $6,858,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of the stock. Apella Capital LLC raised its stake in Bristol Myers Squibb by 55.1% during the first quarter. Apella Capital LLC now owns 12,802 shares of the biopharmaceutical company’s stock worth $770,000 after purchasing an additional 4,549 shares during the period. Focused Wealth Management Inc increased its holdings in shares of Bristol Myers Squibb by 34.1% during the 1st quarter. Focused Wealth Management Inc now owns 5,443 shares of the biopharmaceutical company’s stock worth $330,000 after buying an additional 1,385 shares during the last quarter. Centennial Wealth Advisory LLC acquired a new position in Bristol Myers Squibb in the first quarter valued at $242,000. Faithward Advisors LLC boosted its holdings in Bristol Myers Squibb by 781.3% in the first quarter. Faithward Advisors LLC now owns 42,512 shares of the biopharmaceutical company’s stock valued at $2,578,000 after acquiring an additional 37,688 shares during the last quarter. Finally, Brave Asset Management Inc. grew its position in Bristol Myers Squibb by 16.8% during the first quarter. Brave Asset Management Inc. now owns 5,140 shares of the biopharmaceutical company’s stock valued at $312,000 after acquiring an additional 740 shares during the period. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Insiders Place Their Bets

In related news, EVP David V. Elkins sold 30,000 shares of Bristol Myers Squibb stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the sale, the executive vice president owned 159,248 shares of the company’s stock, valued at $9,820,824.16. The trade was a 15.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.05% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on BMY. Cantor Fitzgerald raised their price objective on Bristol Myers Squibb from $45.00 to $54.00 and gave the stock a “neutral” rating in a report on Wednesday, April 8th. HSBC increased their target price on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a research report on Tuesday, March 17th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Bristol Myers Squibb in a research report on Monday, March 23rd. Citigroup reiterated a “neutral” rating on shares of Bristol Myers Squibb in a research note on Friday, May 1st. Finally, Bank of America dropped their price objective on shares of Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating for the company in a research report on Thursday, April 9th. Eight analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $61.31.

Bristol Myers Squibb Stock Performance

Shares of NYSE:BMY opened at $55.14 on Thursday. The company has a market cap of $112.59 billion, a P/E ratio of 15.49, a PEG ratio of 0.16 and a beta of 0.24. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $62.89. The business’s 50-day simple moving average is $57.13 and its 200 day simple moving average is $57.24.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, topping analysts’ consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The firm had revenue of $11.49 billion during the quarter, compared to analysts’ expectations of $10.93 billion. During the same quarter in the prior year, the business earned $1.80 EPS. Bristol Myers Squibb’s quarterly revenue was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, sell-side analysts forecast that Bristol Myers Squibb Company will post 6.32 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd will be paid a $0.63 dividend. The ex-dividend date is Thursday, July 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.6%. Bristol Myers Squibb’s dividend payout ratio is 70.79%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.